BioCardia details stock and warrant offering

BioCardia, Inc. filed a Form 8-K to report that on September 18, 2025 it issued a press release announcing the pricing of a public offering involving its common stock and warrants.

Rhea-AI Filing Summary

BioCardia, Inc. filed a Form 8-K to report that on September 18, 2025 it issued a press release announcing the pricing of a public offering involving its common stock and warrants. The filing presents this as a Regulation FD disclosure, meaning the company is sharing this capital markets update broadly with investors. The press release is included as Exhibit 99.1, along with an Inline XBRL cover page data file listed as Exhibit 104.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioCardia (BCDA) disclose in this Form 8-K?

BioCardia disclosed that it issued a press release announcing the pricing of a public offering for the purchase and sale of its common stock and warrants, reported under a Regulation FD disclosure item.

When did BioCardia (BCDA) announce the pricing of its public offering?

BioCardia announced the pricing of its public offering on September 18, 2025, as described in the press release referenced in the Form 8-K.

What securities are involved in BioCardia’s public offering?

The public offering described by BioCardia involves the purchase and sale of its common stock and warrants, as stated in the disclosure.

Which exhibit in the Form 8-K contains BioCardia’s press release?

Exhibit 99.1 contains the BioCardia, Inc. press release dated September 18, 2025 that announces the pricing of the public offering.

How is the BioCardia (BCDA) Form 8-K classified under SEC items?

The Form 8-K is classified under Item 7.01, Regulation FD Disclosure, and also lists exhibits under Item 9.01(d).

Who signed the BioCardia Form 8-K related to the offering announcement?

The Form 8-K was signed on behalf of BioCardia, Inc. by Peter Altman, Ph.D., the company’s President and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/18/2025 - 09:15 AM Learn about SEC filing dates

false 0000925741 0000925741 2025-09-18 2025-09-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2025

BIOCARDIA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38999		23-2753988
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

320 Soquel Way
Sunnyvale, California 94085

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 226-0120

_____________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BCDA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 18, 2025, BioCardia, Inc. (the “Company”) issued a press release announcing the pricing of a public offering for the purchase and sale of common stock and warrants. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		BioCardia, Inc. press release dated September 18, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCARDIA, INC.

/s/ Peter Altman, Ph.D.

Peter Altman, Ph.D.

President and Chief Executive Officer

Date: September 18, 2025